{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:06:58Z","timestamp":1791356818025,"version":"4.3.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.anai.2020.07.026","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T02:13:20Z","timestamp":1596161600000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Real-world persistence with dupilumab among adults with atopic dermatitis"],"prefix":"10.1016","volume":"126","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha G.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Mastey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Korotzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Sierka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Jalbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib3","first-page":"110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J\u00a0Clin Cell Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2014.10.037","article-title":"Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection","volume":"135","author":"Esaki","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaci.2018.10.033","article-title":"Human and computational models of atopic dermatitis: a review and perspectives by an expert panel of the International Eczema Council","volume":"143","author":"Eyerich","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/13548500601073928","article-title":"Illness perception in individuals with atopic dermatitis","volume":"12","author":"Wittkowski","year":"2007","journal-title":"Psychol Health Med"},{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/DER.0000000000000401","article-title":"Sleep disturbance and sleep related impairment in adults with atopic dermatitis: a cross-sectional study","volume":"29","author":"Li","year":"2018","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","article-title":"Burden of skin pain in atopic dermatitis","volume":"119","author":"Vakharia","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2020.07.026_bib11","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.jaip.2019.05.055","article-title":"Pain is a common and burdensome symptom of atopic dermatitis in United States adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.anai.2019.06.002","article-title":"Depression and psychological distress in US adults with atopic dermatitis","volume":"123","author":"Cheng","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient-burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1346-8138.14218","article-title":"Burden of atopic dermatitis in Japanese adults: analysis of data from the 2013 National Health and Wellness Survey","volume":"45","author":"Arima","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13555-019-0285-2","article-title":"Understanding the burden of atopic dermatitis in Africa and the Middle East","volume":"9","author":"Al-Afif","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A\u00a0systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Yu","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaci.2006.02.031","article-title":"Patient perspectives on the management of atopic dermatitis","volume":"118","author":"Zuberbier","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2020.07.026_bib26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1346-8138.14116","article-title":"Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis","volume":"45","author":"Wei","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.anai.2019.07.008","article-title":"A\u00a0real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (Quest-AD): baseline treatment patterns and unmet needs assessment","volume":"123","author":"Wei","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.anai.2020.07.026_bib30","series-title":"DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use [prescribing information]","year":"2020"},{"issue":"10013","key":"10.1016\/j.anai.2020.07.026_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.anai.2020.07.026_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","article-title":"Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials","volume":"7","author":"Simpson","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.07.026_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10086","key":"10.1016\/j.anai.2020.07.026_bib39","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2020.07.026_bib43","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag Healthc Policy"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/biomet\/67.1.133","article-title":"Confidence bands for a survival curve from censored data","volume":"67","author":"Hall","year":"1980","journal-title":"Biometrika"},{"issue":"10","key":"10.1016\/j.anai.2020.07.026_bib45","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/03007995.2016.1195733","article-title":"The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2020.07.026_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","article-title":"Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders","volume":"35","author":"Silverberg","year":"2017","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.07.026_bib48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210517","article-title":"Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis","volume":"14","author":"Armstrong","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.anai.2020.07.026_bib51","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/jid.2015.337","article-title":"Association between atopic dermatitis and depression in US adults","volume":"135","author":"Yu","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/DER.0000000000000418","article-title":"Atopic dermatitis and hospitalization for mental health disorders in the United States","volume":"30","author":"Hsu","year":"2019","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis","volume":"79","author":"Ronnstad","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.17683","article-title":"Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2018.08.063","article-title":"Association between atopic dermatitis, depression and suicidal ideation: a systematic review and meta-analysis","volume":"80","author":"Patel","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.07.026_bib56","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review","volume":"12","author":"Murage","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.anai.2020.07.026_bib57","first-page":"201","article-title":"Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis","volume":"21","author":"Feldman","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.anai.2020.07.026_bib58","author":"Sabat\u00e9"},{"issue":"10","key":"10.1016\/j.anai.2020.07.026_bib59","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.07.026_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2012.06.035","article-title":"Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis","volume":"68","author":"Yeung","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.07.026_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620305172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620305172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T15:31:19Z","timestamp":1731166279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620305172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1081120620305172"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.07.026","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world persistence with dupilumab among adults with atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}